Wacker Chemie (WCH) CMD 2026 summary
Event summary combining transcript, slides, and related documents.
CMD 2026 summary
27 Sep, 2026Strategic priorities and portfolio management
Launched REFOCUS, a holistic strategy prioritizing profitability, ROCE, and selective growth in attractive markets, shifting from broad-based expansion to targeted investments and operational excellence.
Introduced differentiated portfolio management with four roles: Accelerate Growth, Optimize Return, Maximize Cash, and Turnaround, each guiding resource allocation and KPIs.
Emphasized innovation and downstream expansion in silicones, commercial excellence in biosolutions, and leadership in core segments including polymers and polysilicon.
Portfolio now managed by granular business units with milestone plans and performance tracking.
Enhanced team capabilities through leadership, digital skills, and AI upskilling programs.
Cost efficiency and operational improvements
PACE program targets over €300 million annual gross savings by 2028, with more than 50% EBITDA-relevant; €85 million already saved in H1 2026.
Organizational restructuring includes reducing 1,600 positions in Germany, merging units, and centralizing support to streamline decision-making.
Completed SAP S/4HANA transformation, enabling AI scaling and advanced data infrastructure.
Lowering break-even point and increasing resilience to invest in innovation and growth.
Financial guidance and capital allocation
Ambition to achieve a structural EBITDA margin of 15% ±2pp and ROCE above 10%, leveraging existing assets and strict capital discipline.
CapEx to remain below depreciation, in the €300–400 million range, prioritizing selective growth and maintenance.
Dividend policy unchanged, targeting 50% of net income, with financial leverage capped at 1x EBITDA.
Sustainability remains integral, with a pathway to Net Zero by 2045, a 43% GHG reduction since 2020, and a 50% reduction target by 2030.
Latest events from Wacker Chemie
- Q2 2026 delivered strong EBITDA growth and progress toward net zero, with a positive FY outlook.WCH
Investor presentation - Q2 sales and EBITDA surged on cost savings and Siltronic gains, but risks from geopolitics persist.WCH
Q2 2026 - Sales and profit declined in 2025, but strategic investments and cost-saving plans aim for recovery.WCH
AGM 2026 - EBITDA rose 45% in Q1 2026 despite a 5% sales drop, with outlook challenged by global risks.WCH
Q1 2026 - Aims for >€10bn sales and >20% EBITDA margin by 2030, driven by innovation and sustainability.WCH
Investor presentation - Q2 2025 saw lower sales and EBITDA, but sustainability and specialty growth remain priorities.WCH
Investor presentation - Restructuring and weak demand led to a net loss, with cost savings and modest growth targeted.WCH
Q4 2025 - Sales and EBITDA declined sharply in Q2 2025, leading to a lower full-year outlook.WCH
Q2 2025 - Q2 sales and EBITDA fell, but chemicals and specialties showed resilience and guidance remains steady.WCH
Q2 2024